Compare AMTX & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | EQ |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.4M | 129.0M |
| IPO Year | 2023 | 2018 |
| Metric | AMTX | EQ |
|---|---|---|
| Price | $1.96 | $3.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $12.00 | $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 922.5K |
| Earning Date | 05-11-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $77,194,000.00 | $41,095,000.00 |
| Revenue This Year | $49.77 | N/A |
| Revenue Next Year | $57.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 174.60 | N/A |
| 52 Week Low | $1.30 | $0.29 |
| 52 Week High | $3.80 | $3.45 |
| Indicator | AMTX | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 61.60 |
| Support Level | $1.38 | $1.54 |
| Resistance Level | $2.25 | $3.45 |
| Average True Range (ATR) | 0.16 | 0.35 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 8.63 | 65.57 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. The operations include California Ethanol, California Dairy Renewable Natural Gas and India Biodiesel. It operates in the reportable geographic segments of North America and India.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.